NCT00720226

Efficacy of Losartan in Preventing Progression of COPD

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: Johns Hopkins University · Academic / Other
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

Evidence in animals shows that losartan can prevent or reverse inflammation and lung damage due to smoking. The goal of this study is to determine whether this drug which is also used to treat hypertension can stabilize or improve lung function in people who have from chronic obstructive pulmonary disease (COPD).

Detailed description

Participants will be given either losartan in a dose of 50-100 mg per day for a period of one year. During that time, they will have lung function tests, breathing tests, and computed tomograms of the chest. These tests will determine whether there is inflammation in the lung and whether there is progressive involvement of the lung with COPD.

Conditions

• COPD
• Emphysema
• Chronic Bronchitis
• Smoking

Interventions

Type	Name	Description
DRUG	Losartan	Losartan 100 mg daily
DRUG	Placebo	Placebo pill daily

Timeline

• Start date: 2008-07-01
• Primary completion: 2014-08-01
• Completion: 2016-08-01
• First posted: 2008-07-22
• Last updated: 2017-04-25
• Results posted: 2017-04-25

Locations

1 site across 1 country: United States